A phase III, double-blind, placebo-controlled study (RAISE) of eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura (ITP)

被引：0
|
作者：
Cheng, G. [1 ]
Saleh, M. N. [2 ]
Bussel, J. B. [3 ,4 ]
Marcher, C. [5 ]
Vasey, S.
Mayer, B. [7 ]
Aivado, M. [6 ]
Arning, M. [6 ]
Stone, N. L. [6 ]
机构：
[1] Chinese Univ Hong Kong, Shatin, Hong Kong, Peoples R China
[2] Georgia Canc Specialists, Atlanta, GA USA
[3] Cornell Univ, Dept Pediat, Div Hematol, Weill Cornell Med Coll, New York, NY USA
[4] Cornell Univ, Dept Med, Div Hematol, Weill Cornell Med Coll, New York, NY USA
[5] Odense Univ Hosp, Odense, Denmark
[6] GlaxoSmithKline, Collegeville, PA USA
[7] GlaxoSmithKline, Stockley Pk, Middx, England
来源：
JOURNAL OF THROMBOSIS AND HAEMOSTASIS | 2009年 / 7卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
AS-MO-055
引用
下载
收藏
页码：25 / 25
页数：1
相关论文
共 50 条
  • [1] Oral Eltrombopag for the Long-Term Treatment of Patients with Chronic Idiopathic Thrombocytopenic Purpura: Results of a Phase III,. Double-Blind, Placebo-Controlled Study (RAISE)
    Cheng, Gregory
    Saleh, Mansoor N.
    Bussel, James B.
    Marcher, Claus
    Vasey, Sandra
    Mayer, Bhabita
    Aivado, Manuel
    Arning, Michael
    Stone, Nicole L.
    BLOOD, 2008, 112 (11) : 153 - 154
  • [2] Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial
    Bussel, James B.
    Provan, Drew
    Shamsi, Tahir
    Cheng, Gregory
    Psaila, Bethan
    Kovaleva, Lidia
    Salama, Abdulgabar
    Jenkins, Julian M.
    Roychowdhury, Debasish
    Mayer, Bhabita
    Stone, Nicole
    Arning, Michael
    LANCET, 2009, 373 (9664): : 641 - 648
  • [3] A Randomized, Double-Blind, Placebo-Controlled Phase 1/2 Study to Determine the Safety and Efficacy of Romiplostim in Children with Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
    Buchanan, George R.
    Bomgaars, Lisa
    Bussel, James B.
    Nugent, Diane J.
    Gnarra, David J.
    Blanchette, Victor S.
    Nie, Kun
    Eisen, Melissa
    Berger, Dietmar
    BLOOD, 2009, 114 (22) : 284 - 285
  • [4] Analysis of bleeding in patients with immune thrombocytopenic purpura (ITP): A randomized, double-blind, placebo-controlled trial of eltrombopag, an oral platelet growth factor.
    Bussel, James B.
    Cheng, Gregory
    Saleh, Mansoor
    Kovaleva, Lidia
    Stone, Nicole
    Mayer, Bhabita
    Jenkins, Julian
    Provan, Andrew
    BLOOD, 2006, 108 (11) : 144A - 144A
  • [5] Levocetirizine in the treatment of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study
    Nettis, E
    Colanardi, MC
    Barra, L
    Ferrannini, A
    Vacca, A
    Tursi, A
    BRITISH JOURNAL OF DERMATOLOGY, 2006, 154 (03) : 533 - 538
  • [6] Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura
    Bussel, James B.
    Cheng, Gregory
    Saleh, Mansoor N.
    Psaila, Bethan
    Kovaleva, Lidia
    Meddeb, Balkis
    Kloczko, Janusz
    Hassani, Habib
    Mayer, Bhabita
    Stone, Nicole L.
    Arning, Michael
    Provan, Drew
    Jenkins, Julian M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (22): : 2237 - 2247
  • [7] ACRIVASTINE VERSUS CLEMASTINE IN THE TREATMENT OF CHRONIC IDIOPATHIC URTICARIA - A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
    JUHLIN, L
    GIBSON, JR
    HARVEY, SG
    HUSON, LW
    INTERNATIONAL JOURNAL OF DERMATOLOGY, 1987, 26 (10) : 653 - 654
  • [8] Rupatadine in the treatment of chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled multicentre study
    Gimenez-Arnau, A.
    Pujol, R. M.
    Ianosi, S.
    Kaszuba, A.
    Malbran, A.
    Poop, G.
    Donado, E.
    Perez, I.
    Izquierdo, I.
    Arnaiz, E.
    ALLERGY, 2007, 62 (05) : 539 - 546
  • [9] The treatment of chronic idiopathic thrombocytopenic purpura (ITP)
    Bakic, M
    Tasic, J
    Pavlovic, M
    MacukanovicGolubovic, L
    Draskovic, S
    THROMBOSIS AND HAEMOSTASIS, 1997, : P1126 - P1126
  • [10] HERCULES - a randomized, double-blind, placebo-controlled, phase 3 study of caplacizumab in patients with acquired thrombotic thrombocytopenic purpura
    Knoebl, P.
    Scully, M.
    Cataland, S.
    Peyvandi, F.
    Coppo, P.
    Hovinga, Kremer J.
    Metjian, A.
    de la Rubia, J.
    Pavenski, K.
    Callewaert, F.
    Biswas, D.
    De Winter, H.
    Zeldin, R. K.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 129 - 130
12345